| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 9,591 | 10,770 | ||
| General and administrative | 5,169 | 5,816 | ||
| Total operating expenses | 14,760 | 16,586 | ||
| Income (loss) from operations | -14,760 | -16,586 | ||
| Interest and investment income (expense) | 1,502 | 1,626 | ||
| Other income (expense) | - | 0 | ||
| Other income (expense), net | 1,502 | 1,626 | ||
| Net income (loss) | -13,258 | -14,960 | ||
| Net unrealized gain (loss) on marketable debt securities | 66 | -12 | ||
| Other comprehensive income (loss) | 66 | -12 | ||
| Comprehensive income (loss) | -13,192 | -14,972 | ||
| Net income (loss) per share attributable to common stockholders, basic (in dollars per share) | -0.31 | -0.35 | ||
| Net income (loss) per share attributable to common stockholders, diluted (in dollars per share) | -0.31 | -0.35 | ||
| Weighted-average shares outstanding, basic (in shares) | 42,272,104 | 42,270,855 | ||
| Weighted-average shares outstanding, diluted (in shares) | 42,272,104 | 42,270,855 | ||
Protara Therapeutics, Inc. (TARA)
Protara Therapeutics, Inc. (TARA)